+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peripheral Drug Eluting Balloon Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 273 Pages
  • August 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5993350
The global market for peripheral drug eluting balloons (DEBs) has witnessed substantial growth, driven by their crucial role in treating cardiovascular conditions, particularly arterial blockages or stenosis. These advanced medical devices merge mechanical dilatation with localized medication delivery, offering an effective solution for addressing vascular lesions.The global peripheral drug-eluting balloon (DEB) market, valued at $942.75 million, is set to reach $1.68 billion with an 8.70% CAGR, driven by their efficacy in treating arterial blockages and stenosis.

Market Dynamics:

  • Paclitaxel Drug Coating Dominance: Paclitaxel-coated DEBs have emerged as a significant segment within the market, reflecting their widespread use and substantial influence. The effectiveness of paclitaxel in preventing restenosis has solidified its position as a preferred choice in the DEB market.
  • Revenue Contribution: Peripheral drug eluting balloons contribute notably to the revenue of the broader peripheral vascular devices market, underscoring their importance in the treatment of vascular conditions.

Increasing Peripheral Arterial Disease Incidence:

Peripheral vascular disease (PVD) involves the narrowing or obstruction of arteries leading to the limbs due to fatty plaque buildup. This condition is increasingly prevalent worldwide, driven by lifestyle factors such as smoking, pollution, and other health issues. The rising incidence of PVD has become a major factor propelling the growth of the DEB market.
  • Lifestyle Impact: The prevalence of peripheral arterial disease (PAD) has escalated due to lifestyle changes, including smoking and exposure to pollution. This growing trend highlights the urgent need for effective treatment options to manage the condition and improve patient outcomes.

Factors Driving Increased Usage of Peripheral Drug Eluting Balloons:

1. Aging Population and Rising Vascular Disease Rates:
  • Geriatric Risk: The aging population is more susceptible to vascular diseases, leading to a heightened demand for peripheral vascular surgeries. As the elderly population grows, so does the need for advanced medical interventions, including DEBs. This demographic shift has created significant opportunities for manufacturers in the DEB market.
  • Demographic Trends: Many countries are experiencing a rapid increase in their elderly populations, contributing to a surge in demand for treatments for vascular conditions. This trend is evident globally, with aging populations driving the need for effective medical solutions like DEBs to manage vascular health.
  • U.S. Projections: The growing elderly population in the U.S. is expected to further drive demand for peripheral drug eluting balloons. As the incidence of peripheral arterial disease rises among older adults, the need for advanced treatment options becomes increasingly critical.

Challenges Facing Market Players:

1. High Product Cost and Limited Clinical Evidence:
  • Cost Constraints: One of the primary barriers to the widespread adoption of peripheral DEBs is their relatively high cost compared to traditional treatments such as angioplasty or stenting. The expenses associated with DEBs, including the device and drug components, can be a deterrent, especially in regions with limited healthcare budgets or reimbursement options.
  • Clinical Evidence: Although DEBs have shown promise in clinical trials, there is a need for more comprehensive and long-term clinical evidence to validate their efficacy and advantages over alternative treatments. The availability of robust, large-scale data is essential for healthcare providers to gain confidence in using DEBs as a standard treatment. The current lack of extensive clinical evidence can impact market adoption and growth.

Regional Insights:

  • United States Market:
  • The U.S. holds a prominent position in the global peripheral drug eluting balloons market, driven by a high prevalence of peripheral arterial disease. The substantial demand for advanced vascular treatments in the U.S. reflects the significant role of DEBs in managing vascular health. The U.S. market's prominence is further supported by the country's focus on addressing the growing incidence of peripheral arterial disease and an aging population.

Competitive Analysis

Key Companies Covered

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Cook Medical Inc.
  • MicroPort Scientific Corporation (Endovastec™)
  • Medtronic Plc.
  • Cardinal Health, Inc.
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Becton, Dickinson and Company
  • W. L. Gore & Associates Inc.
  • Getinge AB
  • Terumo Corp
  • Kyoto Medical Planning Co Ltd
  • iVascular S.L.U
  • AMG International GmbH
  • ENDOCOR GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Nano Therapeutics Pvt Ltd
  • Koninklijke Philips N.V.
  • REVA Medical

Key Segments of Peripheral Drug Eluting Balloons Industry Research

Drug Coating:

  • Paclitaxel Drug Coating
  • Sirolimus drug Coating
  • Others

Indication:

  • Peripheral Arterial Disease
  • Peripheral Aneurysms
  • In-Stent Restenosis
  • Others

Artery Type:

  • Carotid Arteries
  • Fem-Pop Arteries
  • Iliac Arteries
  • Infrapop Arteries

End User:

  • Hospitals
  • Ambulatory Surgical Centers/Outpatients
  • Cardiac Catheterization Labs

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Peripheral Drug Eluting Balloon Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Volume and Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact Of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. Pestle Analysis
3. Production Output and Trade Statistics, 2019-2023
3.1. Global Peripheral Drug Eluting Balloon Market Production Output, by Region, Value (US$ Mn) and Volume (Million Units),2019-2023
3.1.1. North America
3.1.2. Europe
3.1.3. Asia Pacific
3.1.4. Latin America
3.1.5. Middle East and Africa
4. Price Analysis, 2019-2023
4.1. Global Average Price Analysis, by Drug Coating/ Material, US$ Per Unit, 2019-2023
4.2. Prominent Factor Affecting Peripheral Drug Eluting Balloon Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019-2023
5. Global Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
5.1. Global Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
5.1.1. Key Highlights
5.1.1.1. Paclitaxel Drug Coating
5.1.1.2. Sirolimus drug Coating
5.1.1.3. Others
5.2. Global Peripheral Drug Eluting Balloon Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
5.2.1. Key Highlights
5.2.1.1. Peripheral Arterial Disease
5.2.1.2. Peripheral Aneurysms
5.2.1.3. In-Stent Restenosis
5.2.1.4. Others
5.3. Global Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
5.3.1. Key Highlights
5.3.1.1. Carotid Arteries
5.3.1.2. Fem-Pop Arteries
5.3.1.3. Iliac Arteries
5.3.1.4. Infrapop Arteries
5.4. Global Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
5.4.1. Key Highlights
5.4.1.1. Hospitals
5.4.1.2. Ambulatory Surgical Centers/Outpatients
5.4.1.3. Cardiac Catheterization Labs
5.5. Global Peripheral Drug Eluting Balloon Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2019-2031
5.5.1. Key Highlights
5.5.1.1. North America
5.5.1.2. Europe
5.5.1.3. Asia Pacific
5.5.1.4. Latin America
5.5.1.5. Middle East & Africa
6. North America Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
6.1. North America Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.1.1. Key Highlights
6.1.1.1. Peripheral Arterial Disease
6.1.1.2. Peripheral Aneurysms
6.1.1.3. In-Stent Restenosis
6.1.1.4. Others
6.2. North America Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.2.1. Key Highlights
6.2.1.1. Carotid Arteries
6.2.1.2. Fem-Pop Arteries
6.2.1.3. Iliac Arteries
6.2.1.4. Infrapop Arteries
6.3. North America Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Ambulatory Surgical Centers/Outpatients
6.3.1.3. Cardiac Catheterization Labs
6.4. North America Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.4.1. Key Highlights
6.4.1.1. Hospitals
6.4.1.2. Cosmetic & Plastic Surgery Clinics
6.4.1.3. Ambulatory Surgical Centres
6.5. North America Peripheral Drug Eluting Balloon Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1. Key Highlights
6.5.1.1. U.S. Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.2. U.S. Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.3. U.S. Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.4. U.S. Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.5. Canada Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.6. Canada Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.7. Canada Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.1.8. Canada Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Europe Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
7.1. Europe Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.1.1. Key Highlights
7.1.1.1. Peripheral Arterial Disease
7.1.1.2. Peripheral Aneurysms
7.1.1.3. In-Stent Restenosis
7.1.1.4. Others
7.2. Europe Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.2.1. Key Highlights
7.2.1.1. Carotid Arteries
7.2.1.2. Fem-Pop Arteries
7.2.1.3. Iliac Arteries
7.2.1.4. Infrapop Arteries
7.3. Europe Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Ambulatory Surgical Centers/Outpatients
7.3.1.3. Cardiac Catheterization Labs
7.4. Europe Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.4.1. Key Highlights
7.4.1.1. Hospitals
7.4.1.2. Cosmetic & Plastic Surgery Clinics
7.4.1.3. Ambulatory Surgical Centres
7.5. Europe Peripheral Drug Eluting Balloon Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1. Key Highlights
7.5.1.1. Germany Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.2. Germany Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.3. Germany Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.4. Germany Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.5. U.K. Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.6. U.K. Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.7. U.K. Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.8. U.K. Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.9. France Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.10. France Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.11. France Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.12. France Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.13. Italy Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.14. Italy Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.15. Italy Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.16. Italy Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.17. Turkey Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.18. Turkey Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.19. Turkey Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.20. Turkey Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.21. Russia Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.22. Russia Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.23. Russia Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.24. Russia Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.25. Rest Of Europe Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.26. Rest Of Europe Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.27. Rest Of Europe Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.1.28. Rest of Europe Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
8.1. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.1.1. Key Highlights
8.1.1.1. Peripheral Arterial Disease
8.1.1.2. Peripheral Aneurysms
8.1.1.3. In-Stent Restenosis
8.1.1.4. Others
8.2. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.2.1. Key Highlights
8.2.1.1. Carotid Arteries
8.2.1.2. Fem-Pop Arteries
8.2.1.3. Iliac Arteries
8.2.1.4. Infrapop Arteries
8.3. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Ambulatory Surgical Centers/Outpatients
8.3.1.3. Cardiac Catheterization Labs
8.4. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.4.1. Key Highlights
8.4.1.1. Hospitals
8.4.1.2. Cosmetic & Plastic Surgery Clinics
8.4.1.3. Ambulatory Surgical Centres
8.5. Asia Pacific Peripheral Drug Eluting Balloon Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1. Key Highlights
8.5.1.1. China Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.2. China Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.3. China Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.4. China Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.5. Japan Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.6. Japan Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.7. Japan Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.8. Japan Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.9. South Korea Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.10. South Korea Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.11. South Korea Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.12. South Korea Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.13. India Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.14. India Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.15. India Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.16. India Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.17. Southeast Asia Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.18. Southeast Asia Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.19. Southeast Asia Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.20. Southeast Asia Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.21. Rest Of Asia Pacific Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.22. Rest Of Asia Pacific Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.23. Rest Of Asia Pacific Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.1.24. Rest of Asia Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Latin America Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
9.1. Latin America Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.1.1. Key Highlights
9.1.1.1. Peripheral Arterial Disease
9.1.1.2. Peripheral Aneurysms
9.1.1.3. In-Stent Restenosis
9.1.1.4. Others
9.2. Latin America Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.2.1. Key Highlights
9.2.1.1. Carotid Arteries
9.2.1.2. Fem-Pop Arteries
9.2.1.3. Iliac Arteries
9.2.1.4. Infrapop Arteries
9.3. Latin America Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.3.1. Key Highlights
9.3.1.1. Hospitals
9.3.1.2. Ambulatory Surgical Centers/Outpatients
9.3.1.3. Cardiac Catheterization Labs
9.4. Latin America Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.4.1. Key Highlights
9.4.1.1. Hospitals
9.4.1.2. Cosmetic & Plastic Surgery Clinics
9.4.1.3. Ambulatory Surgical Centres
9.5. Latin America Peripheral Drug Eluting Balloon Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1. Key Highlights
9.5.1.1. Brazil Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.2. Brazil Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.3. Brazil Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.4. Brazil Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.5. Mexico Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.6. Mexico Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.7. Mexico Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.8. Mexico Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.9. Argentina Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.10. Argentina Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.11. Argentina Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.12. Argentina Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.13. Rest Of Latin America Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.14. Rest Of Latin America Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.15. Rest Of Latin America Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.1.16. Rest of Latin America Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, 2019-2031
10.1. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.1.1. Key Highlights
10.1.1.1. Peripheral Arterial Disease
10.1.1.2. Peripheral Aneurysms
10.1.1.3. In-Stent Restenosis
10.1.1.4. Others
10.2. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.2.1. Key Highlights
10.2.1.1. Carotid Arteries
10.2.1.2. Fem-Pop Arteries
10.2.1.3. Iliac Arteries
10.2.1.4. Infrapop Arteries
10.3. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.3.1. Key Highlights
10.3.1.1. Hospitals
10.3.1.2. Ambulatory Surgical Centers/Outpatients
10.3.1.3. Cardiac Catheterization Labs
10.4. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.4.1. Key Highlights
10.4.1.1. Hospitals
10.4.1.2. Cosmetic & Plastic Surgery Clinics
10.4.1.3. Ambulatory Surgical Centres
10.5. Middle East & Africa Peripheral Drug Eluting Balloon Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1. Key Highlights
10.5.1.1. GCC Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.2. GCC Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.3. GCC Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.4. GCC Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.5. South Africa Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.6. South Africa Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.7. South Africa Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.8. South Africa Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.9. Egypt Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.10. Egypt Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.11. Egypt Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.12. Egypt Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.13. Nigeria Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.14. Nigeria Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.15. Nigeria Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.16. Nigeria Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.17. Rest Of Middle East & Africa Peripheral Drug Eluting Balloon Market by Drug Coating, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.18. Rest Of Middle East & Africa Peripheral Drug Eluting Balloon Market by Indication, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.19. Rest Of Middle East & Africa Peripheral Drug Eluting Balloon Market by Artery Type, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.1.20. Rest of Middle East & Africa Peripheral Drug Eluting Balloon Market by End User, Value (US$ Mn) and Volume (Million Units), 2019-2031
10.5.2. BPS Analysis/Market Attractiveness Analysis
11. Competitive Landscape
11.1. By Artery Type Vs by Indication Heat Map
11.2. Manufacturer Vs by Indication Heatmap
11.3. Company Market Share Analysis, 2023
11.4. Competitive Dashboard
11.5. Company Profiles
11.5.1. Abbott Laboratories
11.5.1.1. Company Overview
11.5.1.2. Drug Coating Portfolio
11.5.1.3. Financial Overview
11.5.1.4. Business Strategies and Development
11.5.2. Boston Scientific Corporation
11.5.2.1. Company Overview
11.5.2.2. Drug Coating Portfolio
11.5.2.3. Financial Overview
11.5.2.4. Business Strategies and Development
11.5.3. Cook Medical Inc.
11.5.3.1. Company Overview
11.5.3.2. Drug Coating Portfolio
11.5.3.3. Financial Overview
11.5.3.4. Business Strategies and Development
11.5.4. MicroPort Scientific Corporation (Endovastec™)
11.5.4.1. Company Overview
11.5.4.2. Drug Coating Portfolio
11.5.4.3. Financial Overview
11.5.4.4. Business Strategies and Development
11.5.5. Medtronic Plc.
11.5.5.1. Company Overview
11.5.5.2. Drug Coating Portfolio
11.5.5.3. Financial Overview
11.5.5.4. Business Strategies and Development
11.5.6. Cardinal Health, Inc.
11.5.6.1. Company Overview
11.5.6.2. Drug Coating Portfolio
11.5.6.3. Financial Overview
11.5.6.4. Business Strategies and Development
11.5.7. B. Braun Melsungen AG
11.5.7.1. Company Overview
11.5.7.2. Drug Coating Portfolio
11.5.7.3. Financial Overview
11.5.7.4. Business Strategies and Development
11.5.8. BIOTRONIK SE & Co. KG
11.5.8.1. Company Overview
11.5.8.2. Drug Coating Portfolio
11.5.8.3. Financial Overview
11.5.8.4. Business Strategies and Development
11.5.9. Becton, Dickinson and Company
11.5.9.1. Company Overview
11.5.9.2. Drug Coating Portfolio
11.5.9.3. Financial Overview
11.5.9.4. Business Strategies and Development
11.5.10. W. L. Gore & Associates Inc.
11.5.10.1. Company Overview
11.5.10.2. Drug Coating Portfolio
11.5.10.3. Financial Overview
11.5.10.4. Business Strategies and Development
11.5.11. Getinge AB
11.5.11.1. Company Overview
11.5.11.2. Drug Coating Portfolio
11.5.11.3. Financial Overview
11.5.11.4. Business Strategies and Development
11.5.12. Terumo Corp
11.5.12.1. Company Overview
11.5.12.2. Drug Coating Portfolio
11.5.12.3. Financial Overview
11.5.12.4. Business Strategies and Development
11.5.13. Kyoto Medical Planning Co Ltd
11.5.13.1. Company Overview
11.5.13.2. Drug Coating Portfolio
11.5.13.3. Financial Overview
11.5.13.4. Business Strategies and Development
11.5.14. iVascular S.L.U
11.5.14.1. Company Overview
11.5.14.2. Drug Coating Portfolio
11.5.14.3. Financial Overview
11.5.14.4. Business Strategies and Development
11.5.15. AMG International GmbH
11.5.15.1. Company Overview
11.5.15.2. Drug Coating Portfolio
11.5.15.3. Financial Overview
11.5.15.4. Business Strategies and Development
11.5.16. ENDOCOR GmbH
11.5.16.1. Company Overview
11.5.16.2. Drug Coating Portfolio
11.5.16.3. Financial Overview
11.5.16.4. Business Strategies and Development
11.5.17. Meril Life Sciences Pvt. Ltd.
11.5.17.1. Company Overview
11.5.17.2. Drug Coating Portfolio
11.5.17.3. Financial Overview
11.5.17.4. Business Strategies and Development
11.5.18. Nano Therapeutics Pvt Ltd
11.5.18.1. Company Overview
11.5.18.2. Drug Coating Portfolio
11.5.18.3. Financial Overview
11.5.18.4. Business Strategies and Development
11.5.19. Koninklijke Philips N.V.
11.5.19.1. Company Overview
11.5.19.2. Drug Coating Portfolio
11.5.19.3. Financial Overview
11.5.19.4. Business Strategies and Development
11.5.20. REVA Medical
11.5.20.1. Company Overview
11.5.20.2. Drug Coating Portfolio
11.5.20.3. Financial Overview
11.5.20.4. Business Strategies and Development
12. Appendix
12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms And Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Cook Medical Inc.
  • MicroPort Scientific Corporation (Endovastec™)
  • Medtronic Plc.
  • Cardinal Health, Inc.
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Becton, Dickinson and Company
  • W. L. Gore & Associates Inc.
  • Getinge AB
  • Terumo Corp
  • Kyoto Medical Planning Co Ltd
  • iVascular S.L.U
  • AMG International GmbH
  • ENDOCOR GmbH
  • Meril Life Sciences Pvt. Ltd.
  • Nano Therapeutics Pvt Ltd
  • Koninklijke Philips N.V.
  • REVA Medical

Methodology

Loading
LOADING...